154 related articles for article (PubMed ID: 38399491)
1. 2-[
Albano D; Calabrò A; Dondi F; Bertagna F
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399491
[No Abstract] [Full Text] [Related]
2. 2-[
Albano D; Camoni L; Rodella C; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e277-e283. PubMed ID: 33386279
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
4. The role of baseline 2-[
Albano D; Calabrò A; Dondi F; Bagnasco S; Tucci A; Bertagna F
Hematol Oncol; 2024 Mar; 42(2):e3266. PubMed ID: 38444261
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
8. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of baseline
Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F
Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of
Albano D; Camoni L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
[TBL] [Abstract][Full Text] [Related]
12. [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
Dondi F; Albano D; Bertagna F; Giubbini R
Nucl Med Rev Cent East Eur; 2022; 25(2):78-84. PubMed ID: 35848529
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.
Albano D; Mazzoletti A; Spallino M; Muzi C; Zilioli VR; Pagani C; Tucci A; Rossetti C; Giubbini R; Bertagna F
Ann Hematol; 2020 Jun; 99(6):1321-1330. PubMed ID: 32333153
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
15. Relationship between Baseline [
Dondi F; Albano D; Bellini P; Camoni L; Treglia G; Bertagna F
Tomography; 2022 Oct; 8(6):2662-2675. PubMed ID: 36412681
[TBL] [Abstract][Full Text] [Related]
16. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
19. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
Bruzzi JF; Macapinlac H; Tsimberidou AM; Truong MT; Keating MJ; Marom EM; Munden RF
J Nucl Med; 2006 Aug; 47(8):1267-73. PubMed ID: 16883004
[TBL] [Abstract][Full Text] [Related]
20. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
